ClinicalTrials.gg
RecruitingNCT06215027Updated Jan 28, 2025

The Effects of Dance for Breast Cancer Patients Undergoing Surgical Treatment

An interventional study of Dance in Breast Cancer, sponsored by AC Camargo Cancer Center. Recruiting at 1 site in Brazil. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by AC Camargo Cancer Center · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this non randomized clinical trial, with pre- and post-intervention evaluation, longitudinal, with prospective data collection is to evaluate the effects of dance as a therapeutic intervention in breast cancer patients undergoing surgical treatment.

Read the detailed description

The hypothesis is that dance will promote improvements in range of motion, strength, fatigue, functionality, pain and quality of life for breast cancer patients undergoing surgical treatment. Objectives: To evaluate the effects of dance as a therapeutic intervention in breast cancer patients undergoing surgical treatment on: shoulder range of, overall muscle strength, fatigue, respiratory muscle strength, functionality, pain and quality of life. Method: This is a non-randomized randomized clinical trial, with pre- and post-intervention evaluation, prospective data collection. The following will be used for pre-intervention assessment: goniometry, dynamometry, manovacuometry, 6-minute walk test, fatigue and quality of life questionnaire, and quality of life questionnaire, as well as a pain assessment scale. After 16 weeks, the same variables will be assessed.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 30 is below the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

AC Camargo Cancer Center is the lead sponsor of 28 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients diagnosed with breast cancer
  • undergone surgical resection
  • after medical referral for physiotherapy
  • and physiotherapeutic assessment

Exclusion criteria

Exclusion Criteria:

  • patients with another previous oncological diagnosis
  • previous neuromuscular diseases
  • patients who do not agree to take part in the study
  • or the impossibility of carrying out the muscle strength assessment and/or other assessments
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Dance

    Dance

    Other: Dance

Interventions

  • OtherDance

    Dance protocol

06

What researchers measure

Primary outcomes

  1. ROM

    Shoulder range of motion

    Time frame: Pre-intervention and after 16 weeks

Secondary outcomes

  1. Overall muscle strength

    Dynamometer

    Time frame: Pre-intervention and after 16 weeks

  2. Fatigue

    Brief Fatigue Inventory. The BFI is a scale with 11 points (0 to 10), including a dichotomous question about whether the patient felt tired or fatigued in the last 7 days. For each question, zero is considered ''no fatigue'' and 10 is ''worst fatigue possible,'' except for the dichotomous question that is not scored. Among the other questions, 3 measures the severity of fatigue in the current, daily situations, and in the last 24 hours. Six questions measure the influence of fatigue in general activities, mood, walk, work, relationship with other people, and recreation. The total score is the average of all questions. According to the total score, fatigue is classified as mild (1 to 3 points), moderate (4 to 6 points), and severe (7 to 10 points).

    Time frame: Pre-intervention and after 16 weeks

  3. respiratory muscle strength

    Maximum inspiratory and expiratory pressures (MIP and MEP)

    Time frame: Pre-intervention and after 16 weeks

  4. Functionality

    6 minute walk test (6MWT)

    Time frame: Pre-intervention and after 16 weeks

  5. Pain intensity

    Analogic visual scale. The visual analogue pain scale is a measure of pain intensity that has been widely used in several languages. For pain intensity, the scale is most commonly ranging from "no pain" (score of 0) to "worst pain imaginable" (score of 10). A higher rating indicates greater pain intensity.

    Time frame: Pre-intervention and after 16 weeks

  6. Quality of life (physical well-being, social and family well-being, emotional well-being, functional well-being)

    Functional Assessment of Cancer Therapy-Breast (FACT-B). The FACT-B, version 4, is a multidimensional questionnaire composed of 37 questions divided into five domains that assess different dimensions: physical well-being, social and family well-being, emotional well-being, functional well-being and breast cancer subscale.

    Time frame: Pre-intervention and after 16 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06215027
Lead sponsor
AC Camargo Cancer Center
Responsible party
Leticia Zumpano Cardenas (PHD, physiotherapist at the intensive care unit, stricto sensu postgraduate professor, AC Camargo Cancer Center) — Principal investigator
First posted
Jan 22, 2024
Start date
Feb 1, 2024
Primary completion
Dec 10, 2025 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Jan 28, 2025

Study contacts

Letícia Cardenas, PHD
Contact
leticia.cardenas@accamargo.org.br
5511985742277
Letícia Cardenas, PHD
principal investigator · AC Camargo Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion